Cancer Immunotherapy

Turning Dreams into Reality: Roche’s CD3 Bispecific Antibody Combined ADC Shows Exceptional Efficacy, Expanding the CD3 Bispecific ADC Concept

by
Turning Dreams into Reality: Roche's CD3 Bispecific Antibody Combined ADC Shows Exceptional Efficacy, Expanding the CD3 Bispecific ADC Concept

▎Trace Back Three years ago, when I wrote analyses on the CD3 bispecific antibody combined ADC, it was often considered an overly aggressive therapy. However, Roche has made significant explorations in this area. When the CD3/DLL3 ADC from Wuxi Biologics was released, many in the industry were puzzled, but there is no need for surprise. … Read more

The Evolution of Antibody-Drug Conjugates (ADCs): Opportunities and Challenges

by
The Evolution of Antibody-Drug Conjugates (ADCs): Opportunities and Challenges

At this year’s AACR annual meeting, there were hundreds of details related to ADC drugs. Leading ADC company Daiichi Sankyo announced the latest research progress of its HER3-targeted ADC product Patritumab deruxtecan (HER3-DXd); AstraZeneca also disclosed research updates on several drugs including AZD9592 (bispecific ADC) and AZD5335 (FRα ADC). Many Chinese pharmaceutical companies also showcased … Read more

A Multi-Threshold Micelle Improves Tumor Accumulation and STING Immunotherapy

by
A Multi-Threshold Micelle Improves Tumor Accumulation and STING Immunotherapy

In the field of cancer immunotherapy, activating STING (Stimulator of Interferon Genes) is a key strategy to stimulate anti-cancer immune responses. STING, as an important innate immune protein, enhances anti-cancer immunity through type I interferon signaling. However, traditional STING agonists face numerous challenges during intravenous administration, such as short blood circulation half-life and insufficient tumor … Read more

Objective Response Rate Reaches 80%! GCC19CAR-T Brings New Hope to Patients with Advanced Colorectal Cancer

by

One patient had all tumor target lesions disappear, achieving complete remission,80% of patients experienced significant tumor reduction, and the novel GCC19CAR-T brings new hope to patients with advanced colorectal cancer! Globally, colorectal cancer (CRC) has become the third most common malignant tumor and the second leading cause of cancer-related deaths. Currently, metastatic colorectal cancer primarily … Read more

Professor Liu Yunjian: Interpreting the DS8201-A-U105 Study and Discussing the Future of ADC Combined Immunotherapy

by
Professor Liu Yunjian: Interpreting the DS8201-A-U105 Study and Discussing the Future of ADC Combined Immunotherapy

Introduction The DS8201-A-U105 study reveals the latest advancements in ADC combined immunotherapy. What insights can we draw from it? The annual European Society for Medical Oncology Breast Cancer (ESMO BC) conference was officially held from May 3-5, 2022, reporting a series of significant advancements in the field of breast cancer. ADCs have become star drugs … Read more

Advances in Diagnosis and Treatment of Intrahepatic Cholangiocarcinoma

by
Advances in Diagnosis and Treatment of Intrahepatic Cholangiocarcinoma

Abstract: Intrahepatic cholangiocarcinoma (ICC) is a relatively rare type of primary liver cancer, with an increasing incidence in recent years. Due to its insidious onset and atypical clinical symptoms, most patients are diagnosed at an advanced stage of the disease, making timely diagnosis and treatment crucial. The standard treatment for early-stage ICC patients is radical … Read more

2023 ESMO: B7-H3 Targeted ADCs Show Exceptional Efficacy in SCLC and sqNSCLC

by
2023 ESMO: B7-H3 Targeted ADCs Show Exceptional Efficacy in SCLC and sqNSCLC

Updates on the first human study data from Phase I/II show that B7-H3 targeted ADCs continue to demonstrate therapeutic potential. In recent years, antibody-drug conjugates (ADCs) have emerged as a new class of drugs that bring new “hope” to the treatment of advanced cancer patients due to their unique mechanisms of action. The B7 family … Read more

DAC, ISAC, and Dual Payload ADC: Who Will Lead the Next Generation of ADC Technology Innovation?

by
DAC, ISAC, and Dual Payload ADC: Who Will Lead the Next Generation of ADC Technology Innovation?

If a few years ago, presenting a simple PowerPoint on the ADC field could impress without the need for future visions, cutting-edge technologies, or a vibrant pipeline forest, today, the ADC field requires substantial content to make an impact. This shift is attributed to advancements in industry technology and rising awareness. Data shows that from … Read more

High-Dose Vitamin C Precision Therapy for Tumors

by
High-Dose Vitamin C Precision Therapy for Tumors

Source: Wang Xin, Rao Benqiang. High-Dose Vitamin C Precision Therapy for Tumors [J/CD]. Journal of Tumor Metabolism and Nutrition, 2023, 10(3): 307-312. Article link: http://182.92.200.144/CN/abstract/abstract1016.shtml Expert Introduction Rao Benqiang, Deputy Director of the Second Department of Gastrointestinal Surgery at Beijing Shijitan Hospital, Capital Medical University, Deputy Director of the National Market Supervision Key Laboratory (Tumor … Read more

In-Depth Analysis of ADCs: Part Two

by
In-Depth Analysis of ADCs: Part Two

Introduction Antibodies are one of the key components of ADC drugs, serving as precise guiding components with the functions of targeting and toxin delivery. They can specifically recognize the target antigens on the surface of tumor cells, delivering toxins to the tumor cells and mediating the localization and endocytosis of ADCs in tumor cells[1]. After … Read more